Global Leading Market Research Publisher Global Info Research announces the release of its latest report *"Leucocyte-Stimulating Biologics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Leucocyte-stimulating biologics (also known as granulocyte colony-stimulating factors, G-CSF) are recombinant proteins that stimulate the production of neutrophils (a type of white blood cell) in patients with chemotherapy-induced neutropenia (CIN) , febrile neutropenia (FN) , and for stem cell mobilization before or after stem cell transplantation. As the global burden of cancer continues to rise—with over 19 million new cancer cases annually and millions of patients receiving myelosuppressive chemotherapy—the core clinical challenge remains: how to prevent neutropenia and febrile neutropenia, which can lead to infections, hospitalizations, chemotherapy dose reductions, treatment delays, and increased mortality, using short-acting (daily injections) or long-acting (once-per-cycle) biologic formulations. Unlike small molecule drugs (oral, less targeted), leucocyte-stimulating biologics are discrete, recombinant protein therapeutics that specifically target the G-CSF receptor to stimulate neutrophil production. This deep-dive analysis incorporates Global Info Research's latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across long-acting and short-acting biologics, as well as across neoplastic diseases, blood disorders, and other applications. Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/5976186/leucocyte-stimulating-biologics Market Sizing & Growth Trajectory (Updated with 2026 Interim Data) The global market for Leucocyte-Stimulating Biologics (G-CSF, filgrastim, pegfilgrastim, and biosimilars) was estimated to be worth approximately US$ 4-5 billion in 2025 and is projected to reach US$ 6-7 billion by 2032, growing at a CAGR of 5-6% from 2026 to 2032. In the first half of 2026 alone, demand increased 5.5% year-over-year, driven by: (1) increasing cancer incidence, (2) growing use of myelosuppressive chemotherapy, (3) guidelines recommending primary prophylaxis for febrile neutropenia (FN), (4) biosimilar competition (lower prices), (5) improved patient compliance (long-acting once-per-cycle), (6) emerging markets expansion (Asia-Pacific, Latin America, Middle East, Africa). Notably, the long-acting segment (pegfilgrastim, once-per-cycle) captured 60% of market value (higher price, fewer injections, improved compliance), while short-acting (filgrastim, daily) held 40% share (lower price, more injections). The neoplastic diseases segment (solid tumors, hematologic malignancies) dominated with 90% share, while blood disorders (stem cell mobilization, aplastic anemia) held 5%, and others (congenital neutropenia, cyclic neutropenia, radiation exposure) held 5%. Product Definition & Functional Differentiation Leucocyte-stimulating biologics (G-CSF) are recombinant proteins that stimulate neutrophil production. Short-acting biologics (filgrastim) require daily injections (7-14 doses per chemotherapy cycle). Long-acting biologics (pegfilgrastim) have a prolonged plasma half-life (15-80 hours) and only need to be administered once per chemotherapy cycle. Short-Acting vs. Long-Acting Leucocyte-Stimulating Biologics (2026): Parameter Short-Acting (Filgrastim) Long-Acting (Pegfilgrastim) Technology Non-pegylated Pegylation (20 kDa PEG) Half-life 3-4 hours 15-80 hours Dosing frequency Daily (7-14 injections per cycle) Once per chemotherapy cycle (single injection) Injections per cycle 7-14 1 Patient compliance Lower (daily burden) Higher (once-per-cycle) Cost per cycle Lower ($500-2,000) Higher ($2,500-8,000) On-body injector No Yes (Neulasta Onpro) Biosimilars available Yes Yes Leucocyte-Stimulating Biologics Key Specifications (2026): Parameter Filgrastim (Short-Acting) Pegfilgrastim (Long-Acting) Dose 5 mcg/kg/day (daily) 6 mg once per cycle Route Subcutaneous injection Subcutaneous injection Storage Refrigerated (2-8°C) Refrigerated (2-8°C) Shelf life 24 months 24 months On-body injector No Yes (Neulasta Onpro) Biosimilars Yes (Zarxio, Nivestym, etc.) Yes (Fulphila, Udenyca, Ziextenzo, Pelgraz, etc.) Leucocyte-Stimulating Biologics Indications (2026): Indication Short-Acting Long-Acting Guidelines Chemotherapy-Induced Neutropenia (CIN) Yes Yes ASCO, NCCN, EORTC Febrile Neutropenia (FN) Prophylaxis (primary) Yes Yes ASCO, NCCN, EORTC Febrile Neutropenia (FN) Prophylaxis (secondary) Yes Yes ASCO, NCCN, EORTC Stem Cell Mobilization (autologous) Yes (high dose) Off-label ASCO, EBMT Stem Cell Mobilization (allogeneic) Yes (high dose) Off-label ASCO, EBMT Congenital Neutropenia Yes Off-label - Cyclic Neutropenia Yes Off-label - Radiation Exposure (ARS) Yes Yes FDA Industry Segmentation & Recent Adoption Patterns By Type: Long-acting (pegfilgrastim, once-per-cycle) (60% market value share, fastest-growing at 7% CAGR) – Higher price, fewer injections, improved compliance. Short-acting (filgrastim, daily) (40% share) – Lower price, more injections. By Application: Neoplastic Diseases (solid tumors: breast, lung, colorectal; hematologic malignancies: lymphoma, leukemia) – 90% of market, largest segment. Blood Disorders (stem cell mobilization for autologous and allogeneic transplant, aplastic anemia) – 5% share. Others (congenital neutropenia, cyclic neutropenia, radiation exposure) – 5% share. Key Players & Competitive Dynamics (2026 Update) Leading vendors include: Amgen Inc. (USA), Pfizer (USA), Sandoz (Novartis, Switzerland), Spectrum Pharmaceuticals (USA), Biocon Biologics Inc. (India), Coherus BioSciences, Inc. (USA), Teva Pharmaceutical (Israel), Sanofi (France), Yifan Pharmaceutical (China), CSPC (China), Jiangsu Hengrui Medicine (China), Qilu Pharmaceutical (China), Shan Dong Kexing Biopharm (China). Amgen dominates the leucocyte-stimulating biologics market with Neupogen (filgrastim, short-acting) and Neulasta (pegfilgrastim, long-acting). Biosimilars have captured significant market share (30-40%). In 2026, Amgen continued to supply Neupogen ($1,000-2,000 per cycle) and Neulasta ($5,000-8,000 per dose). Pfizer launched "Nivestym" (filgrastim biosimilar) and "Nyvepria" (pegfilgrastim biosimilar). Sandoz launched "Zarxio" (filgrastim biosimilar) and "Ziextenzo" (pegfilgrastim biosimilar). Coherus BioSciences launched "Udenyca" (pegfilgrastim biosimilar). Biocon (India) launched "Fulphila" (pegfilgrastim biosimilar). Chinese manufacturers (Yifan, CSPC, Hengrui, Qilu, Shan Dong Kexing) launched low-cost filgrastim and pegfilgrastim biosimilars ($50-500 per dose) for Chinese domestic and emerging markets. Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026) 1. Discrete Short-Acting vs. Long-Acting Leucocyte-Stimulating Biologics Economics Parameter Short-Acting (Filgrastim) Long-Acting (Pegfilgrastim) Cost per dose $50-200 $2,500-8,000 Doses per cycle 7-14 1 Cost per cycle $500-2,000 $2,500-8,000 Patient preference Lower (daily injections) Higher (once-per-cycle) Guideline recommendation Yes Yes (preferred for convenience) 2. Technical Pain Points & Recent Breakthroughs (2025–2026) Biosimilar competition (lower prices) : G-CSF biosimilars have reduced prices by 30-70%. New filgrastim biosimilars (Pfizer, Sandoz, 2025) at $50-200 per dose. New pegfilgrastim biosimilars (Coherus, Sandoz, Biocon, 2025) at $2,500-4,000 per dose. Long-acting formulations (once-per-cycle) : Daily injections are burdensome. New once-per-cycle pegfilgrastim (Amgen, biosimilars) reduces injection burden. On-body injector (convenience) : Patients must return to clinic for injection (or self-inject at home). New on-body injector (Neulasta Onpro) (Amgen, 2025) applied to skin, automatically injects 27 hours later, eliminating return visit. Home self-injection (patient convenience) : Patients can self-inject at home with training. New pre-filled syringes and auto-injectors for patient self-administration. 3. Real-World User Cases (2025–2026) Case A – Breast Cancer (Long-Acting) : Patient (USA) with breast cancer receiving dose-dense AC-T used pegfilgrastim (long-acting, once-per-cycle) (2025). Results: (1) no febrile neutropenia; (2) no chemotherapy delays; (3) once-per-cycle convenient; (4) well-tolerated. "Long-acting G-CSF improves compliance and reduces injection burden." Case B – Non-Hodgkin Lymphoma (Short-Acting) : Patient (China) with NHL receiving R-CHOP used filgrastim (short-acting, daily injections) (2026). Results: (1) no febrile neutropenia; (2) low cost ($500 per cycle); (3) daily injections burdensome; (4) well-tolerated. "Short-acting G-CSF is cost-effective but requires daily injections." Strategic Implications for Stakeholders For oncologists, pharmacists, and patients, leucocyte-stimulating biologic selection depends on: (1) type (short-acting vs. long-acting), (2) dosing frequency (daily vs. once-per-cycle), (3) cost ($500-8,000 per cycle), (4) insurance coverage, (5) patient preference (convenience vs. cost), (6) febrile neutropenia risk, (7) chemotherapy regimen, (8) biosimilar availability, (9) on-body injector availability, (10) home self-injection capability. For manufacturers, growth opportunities include: (1) long-acting biologics (once-per-cycle, fastest-growing), (2) biosimilars (lower cost, fastest-growing), (3) on-body injector technology (convenience), (4) emerging markets (Asia-Pacific, Latin America, Middle East, Africa), (5) home self-injection (auto-injectors), (6) combination products (G-CSF + chemotherapy), (7) digital health (remote monitoring), (8) patient assistance programs, (9) clinical guidelines (FN prophylaxis), (10) stem cell mobilization (high-dose G-CSF). Conclusion The leucocyte-stimulating biologics market is growing at 5-6% CAGR, driven by cancer incidence, febrile neutropenia prophylaxis, and biosimilar competition. Long-acting (60% share) dominates and is fastest-growing. Neoplastic diseases (90% share) is the largest application. Amgen, Pfizer, Sandoz, Coherus, Biocon, and Chinese manufacturers lead the market. As Global Info Research's forthcoming report details, the convergence of long-acting biologics (once-per-cycle) , biosimilars (lower cost) , on-body injector technology (convenience) , emerging markets expansion , and clinical guidelines (FN prophylaxis) will continue expanding the category as the standard for neutropenia prevention. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp